Literature DB >> 8623529

Preliminary crystallographic studies of bacteriophage T4 fibritin confirm a trimeric coiled-coil structure.

S V Strelkov1, Y Tao, M G Rossmann, L P Kurochkina, M M Shneider, V V Mesyanzhinov.   

Abstract

Fibritin, a 52-kDa product of gene wac of bacteriophage T4, forms fibrous "whiskers" that connect to the phage tail and facilitate the later stages of phage assembly. Preliminary experiments suggest that fibritin is a trimer, and its predominant central part has a parallel alpha-helical coiled-coil structure. To investigate the oligomerization and function of fibritin, we have designed and studied two related deletion mutants, denoted M and E, that consist of its last 75 and 120 amino acids, respectively. Both proteins contain part of the coiled-coil region and the 29 amino acid carboxy-terminal domain essential for the trimerization of fibritin. The proteins are expressed as a soluble product in an Escherichia coli system. We have obtained crystals of fibritins M and E. Complete native X-ray diffraction data sets have been collected to 1.85 and 2.7 A resolution, respectively. The crystals have space group P3 with a=44.3 A, c=91.3 A (fibritin M) and R32 with a=41.2 A, b=358.7 A (fibritin E) in the hexagonal setting. Symmetry and packing considerations show that fibritin is a triple coiled coil.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8623529     DOI: 10.1006/viro.1996.0236

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  2 in total

Review 1.  Bacteriophage T4 genome.

Authors:  Eric S Miller; Elizabeth Kutter; Gisela Mosig; Fumio Arisaka; Takashi Kunisawa; Wolfgang Rüger
Journal:  Microbiol Mol Biol Rev       Date:  2003-03       Impact factor: 11.056

2.  A New Gorilla Adenoviral Vector with Natural Lung Tropism Avoids Liver Toxicity and Is Amenable to Capsid Engineering and Vector Retargeting.

Authors:  Zhi Hong Lu; Igor P Dmitriev; Douglas E Brough; Elena A Kashentseva; Jie Li; David T Curiel
Journal:  J Virol       Date:  2020-05-04       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.